Abilify

Irritability, Schizophrenia, Agitation + 10 more

Treatment

1 FDA approval

20 Active Studies for Abilify

What is Abilify

Aripiprazole

The Generic name of this drug

Treatment Summary

Aripiprazole is a medication used to treat mental health conditions like schizophrenia, bipolar disorder, major depression, irritability in people with autism, and Tourette's syndrome. It can be taken orally or given as an injection to treat agitation related to schizophrenia or bipolar mania. Aripiprazole works by stimulating dopamine and serotonin receptors while inhibiting alpha-adrenergic and serotonin receptors. This drug was approved by the FDA in 2002.

Abilify

is the brand name

image of different drug pills on a surface

Abilify Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Abilify

Aripiprazole

2002

454

Approved as Treatment by the FDA

Aripiprazole, also known as Abilify, is approved by the FDA for 1 uses such as Schizophrenia .

Schizophrenia

Used to treat Schizophrenia in combination with Aripiprazole lauroxil

Effectiveness

How Abilify Affects Patients

Aripiprazole binds strongly to various receptors in the brain, such as those for serotonin, dopamine, and adrenaline. It also has weaker effects on other receptors. It is not yet known exactly how this binding of aripiprazole to these receptors results in its clinical effects.

How Abilify works in the body

Aripiprazole works to treat psychosis by activating dopamine and serotonin receptors. It may also cause unwanted side effects by affecting other receptors, such as the adrenergic alpha1 receptor, which can cause low blood pressure when standing.

When to interrupt dosage

The recommended dosage of Abilify is contingent upon the diagnosed condition, including Agitation, Schizophrenia and Alzheimer's Disease. The quantity of dosage is dependent on the mode of delivery noted in the table below.

Condition

Dosage

Administration

Schizophrenia

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Irritability

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Bipolar Disorder

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Acute Coryza

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Alzheimer's Disease

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Psychotic Depression

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Schizophrenia

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Agitation

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Autism Spectrum Disorder (ASD)

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Tourette Syndrome

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Bipolar Disorder

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Bipolar Disorder

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Depression

, 5.0 mg, 10.0 mg, 20.0 mg, 30.0 mg, 15.0 mg, 2.0 mg, 300.0 mg, 400.0 mg, 1.0 mg/mL, 9.75 mg/mL, 400.0 mg/mL, 300.0 mg/mL, 7.5 mg/mL

Tablet - Oral, Tablet, , Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Solution, Solution - Oral, Injection, solution - Intramuscular, Injection, solution, Injection, powder, lyophilized, for suspension, extended release - Intramuscular, Injection, powder, lyophilized, for suspension, extended release, Injection, Injection - Intramuscular

Warnings

Abilify Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Aripiprazole may interact with Pulse Frequency

There are 20 known major drug interactions with Abilify.

Common Abilify Drug Interactions

Drug Name

Risk Level

Description

Acepromazine

Major

Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Aripiprazole is combined with Aclidinium.

Alfuzosin

Major

Aripiprazole may increase the hypotensive activities of Alfuzosin.

Amisulpride

Major

Aripiprazole may increase the antipsychotic activities of Amisulpride.

Aripiprazole lauroxil

Major

Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole lauroxil.

Abilify Toxicity & Overdose Risk

There have been no studies done on the safety and effectiveness of taking aripiprazole while pregnant. However, a national pregnancy registry is tracking mothers who take it while pregnant. Studies of other antipsychotic medications during pregnancy have found that babies are at risk of developing symptoms like muscle stiffness or withdrawal. Animal studies of aripiprazole have linked it to birth defects and fetal death at higher doses than the recommended for humans. Aripiprazole should only be prescribed if the benefits outweigh the risks. Babies exposed to the drug in the third trimester may develop symptoms like muscle stiffness or withdrawal that can last from hours to

image of a doctor in a lab doing drug, clinical research

Abilify Novel Uses: Which Conditions Have a Clinical Trial Featuring Abilify?

Currently, 469 active clinical trials are underway to ascertain the potential of Abilify in treating Alzheimer's Disease, Early Infantile Autism and Irritability.

Condition

Clinical Trials

Trial Phases

Schizophrenia

97 Actively Recruiting

Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2

Bipolar Disorder

0 Actively Recruiting

Bipolar Disorder

0 Actively Recruiting

Acute Coryza

1 Actively Recruiting

Not Applicable

Alzheimer's Disease

15 Actively Recruiting

Not Applicable, Phase 2, Phase 1

Psychotic Depression

0 Actively Recruiting

Irritability

8 Actively Recruiting

Phase 2, Not Applicable, Early Phase 1, Phase 4

Schizophrenia

31 Actively Recruiting

Early Phase 1, Not Applicable, Phase 4

Agitation

3 Actively Recruiting

Phase 2, Phase 3, Not Applicable

Bipolar Disorder

0 Actively Recruiting

Autism Spectrum Disorder (ASD)

60 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 1, Phase 4, Early Phase 1

Depression

213 Actively Recruiting

Phase 3, Phase 2, Not Applicable, Phase 4, Phase 1, Early Phase 1

Tourette Syndrome

3 Actively Recruiting

Not Applicable

Abilify Reviews: What are patients saying about Abilify?

5

Patient Review

6/18/2022

Abilify for Additional Medications to Treat Depression

I've been on Trintellix for a few years now and, recently, I had been feeling very depressed and suicidal. However, my psychiatrist put me on Abilify and, after just three days, I'm virtually depression-free! This feels like a miracle to me; I haven't felt this good in years!

5

Patient Review

6/30/2022

Abilify for Bipolar I Disorder with Most Recent Episode Mixed

Abilify has worked very well for me over the last five years. It's important to remember that people react differently to medications, so what works for one person might not work for another.

4.7

Patient Review

9/15/2022

Abilify for Additional Medications to Treat Depression

This treatment has been working great for me. I have seen a significant reduction in my depression symptoms, which has had a positive impact on my quality of life. I have experienced some side effects, but they are manageable and haven't impacted my ability to live a normal life.

4.7

Patient Review

9/9/2022

Abilify for Additional Medications to Treat Depression

My kids think this is for schizophrenia. This is dangerous to translate because they are from broken homes and it's safe to say I am not any longer. It has several uses, but I use it for depression. Strong.

3.3

Patient Review

11/6/2022

Abilify for Additional Medications to Treat Depression

While this did an amazing job at stabilizing my mood, the side effects were just too much for me to handle. My anxiety increased significantly while taking this medication and made it hard to focus on anything else or go about my daily routine.

1

Patient Review

7/22/2022

Abilify for Additional Medications to Treat Depression

Do not under any circumstances take this drug. It completely ruined my life by causing me to gain an excessive amount of weight and develop a gambling addiction. The company who makes it, Bristol-Meyers, claims they did nothing wrong but I disagree.

1

Patient Review

9/1/2022

Abilify for Schizophrenia

ABILIFY is poison and caused me to become a compulsive gambler. It's completely useless and should be illegal. The company that manufactures it is scamming American taxpayers by making insurance companies pay outrageous prices for their drug.

1

Patient Review

9/16/2022

Abilify for Bipolar Disorder in Remission

As a child, I was prescribed this medication and it caused me to have uncontrollable muscle spasms in my jaw. My mouth was stuck shut and I came dangerously close to breaking my jaw. All the psychiatrist did was lower my dosage, but I was forced to take this for 2 years due to my age. Now, 18 years later, I suffer from chronic TMJ as a result of long-term side effects.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about abilify

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the drug Abilify used for?

"Aripiprazole is a medication that can be used to treat mental disorders such as bipolar I disorder, major depressive disorder, and schizophrenia. It can be used by itself or in combination with other medications."

Answered by AI

What are the negative side effects of Abilify?

"The following side effects may occur: dizziness, lightheadedness, drowsiness, nausea, vomiting, tiredness, excess saliva/drooling, blurred vision, weight gain, constipation, headache, and trouble sleeping. If you experience any of these effects, tell your doctor or pharmacist."

Answered by AI

Is Abilify an antipsychotic or mood stabilizer?

"Abilify is an antipsychotic medication that affects chemicals in the brain to treat the symptoms of psychotic conditions like schizophrenia in adults and children aged 13 and up."

Answered by AI

Is Abilify an antipsychotic or antidepressant?

"The medicine Abilify is used to treat a variety of mental disorders, such as schizophrenia, bipolar disorder, Tourette syndrome, and irritability associated with autism. It can be used in combination with an antidepressant to treat depression."

Answered by AI

Clinical Trials for Abilify

Image of University of Virginia in Charlottesville, United States.

Low-Tech AAC for Autism

3 - 14
All Sexes
Charlottesville, VA

Many people with autism and other developmental conditions have difficulty speaking or do not use speech and need other ways to communicate. Augmentative and alternative communication (AAC) includes tools such as picture boards, communication books, and gestures that support communication. In low-resource settings and underserved rural areas in the United States, high-tech AAC devices are often too expensive or difficult to access, and trained specialists are limited. Low-tech AAC options are more affordable but are often not used successfully because tools may not match the individual's abilities or daily environment, caregivers and providers may lack training, and stigma or low awareness may discourage use. These challenges can lead to AAC abandonment and social isolation. Rural Virginia and western Kenya face similar barriers, including limited AAC expertise, inconsistent assessment, and insufficient training for families, educators, and community providers. This project uses a shared learning approach that combines western Kenya's experience implementing low-tech AAC in new settings with rural Virginia's expertise in individualized assessment, training, and scalable service delivery. The goal is to better match individuals to appropriate low-tech AAC systems and support communication partners to use them effectively.

Waitlist Available
Has No Placebo

University of Virginia

Eren Oyungu, MBChB

Have you considered Abilify clinical trials?

We made a collection of clinical trials featuring Abilify, we think they might fit your search criteria.
Go to Trials
Image of Pennsylvania Hospital in Philadelphia, United States.

Electroconvulsive Therapy for Depression

Any Age
All Sexes
Philadelphia, PA

The goal of this clinical trial is to improve how electroconvulsive therapy (ECT) stimulation settings are chosen. Researchers will use real-time brain monitoring to measure both seizures and a recently identified brain event called cortical spreading depolarization (CSD). The main questions it aims to answer are: What is the best way to increase ECT stimulation settings? How do different pulse settings affect the brain's response? Can certain settings produce CSD without causing a seizure? Participants already receiving ECT as part of their care will take part. They will be assigned to one of two groups: Index ECT group: Participants starting ECT will receive different standard titration approaches. Maintenance ECT group: Participants receiving ongoing ECT will undergo a brief, low-dose stimulation test before treatment. All participants will be monitored using brain physiology (EEG and blood flow) and symptom scales during treatment.

Waitlist Available
Has No Placebo

Pennsylvania Hospital

Image of McLean Hospital in Belmont, United States.

Theta Burst Stimulation for Depression

18+
All Sexes
Belmont, MA

Many people with depression do not get better with standard treatments like medication. One promising alternative is transcranial magnetic stimulation (TMS), a non-invasive procedure that uses magnetic pulses to stimulate specific brain regions. A particular pattern of TMS called continuous theta-burst stimulation (cTBS) is thought to reduce overactive brain activity in depression, but the investigators do not yet fully understand how it works at the level of brain cells and connections. This study aims to determine the biological mechanism by which cTBS changes brain activity in people with depression. Specifically, the investigators are testing two competing ideas: (1) that cTBS works by weakening the connections between brain cells through a process called long-term depression (LTD), which is driven by a chemical messenger system called glutamate; or (2) that cTBS works by increasing the brain's natural "braking" system, driven by a different chemical messenger called GABA. To test these ideas, participants with depression will receive cTBS along with one of four FDA-approved medications, or placebo, that either boost or block these chemical messenger systems. The investigators will measure changes in brain activity using electroencephalography (EEG) recorded simultaneously with TMS. Specific patterns in the EEG signal, called TMS-evoked potentials (TEPs), act as a window into how different brain cell types are responding to stimulation. Each participant will complete four study visits, each testing a different drug-TMS combination in random order. One group of participants will test drugs targeting the glutamate system (d-cycloserine and memantine). A second group will test drugs targeting the GABA system (lorazepam and baclofen). All drugs are given as a single oral dose and are commonly used in clinical practice. Understanding exactly how cTBS works at a biological level could open the door to more effective, personalized TMS treatments.

Phase < 1
Recruiting

McLean Hospital

Joshua C Brown, MD, PhD

Image of Wake Forest University Health Sciences in Winston-Salem, United States.

Auditory Stimulation for Insomnia

20 - 50
All Sexes
Winston-Salem, NC

The goal of this clinical trial is to determine if alpha phase-locked auditory stimulation can improve sleep in people with insomnia and depression. The main goals of the pilot study are the following: Determine whether alpha phase-locked auditory stimulation (active stimulation) improves objective and subjective sleep in individuals with insomnia and depression. The study team hypothesizes that active auditory stimulation will reduce objective and subjective sleep onset latency (SL) and wake after sleep onset (WASO) compared to a sham stimulation. Participants will: * Wear Elemind Neuromod headband nightly for 4 weeks (1 week baseline, 1 week active/sham stimulation, 1 week washout, and 1 week opposite condition - active/sham stimulation) * Wear actigraphy watch for duration of the study * Complete questionnaires regarding their sleep, mood, and satisfaction with the device

Waitlist Available
New This Month

Wake Forest University Health Sciences

Ruth Benca, MD, PhD

Have you considered Abilify clinical trials?

We made a collection of clinical trials featuring Abilify, we think they might fit your search criteria.
Go to Trials
Image of Indiana Institute on Disability and Community in Bloomington, United States.

Digital Coaching for Autism

18 - 35
All Sexes
Bloomington, IN

There is a need and opportunity to improve the supports, transitions, and life outcomes of people with autism spectrum disorder. Compared to their neurotypical peers, autistic teenagers and adults report poorer mental health and quality of life and have higher rates of unemployment or underemployment and low participation in post-secondary education. Nearly 40% spend little or no time with friends. Although autism awareness has grown considerably in recent decades, much more can be done to improve the life outcomes for people with autism. Cost-effective, affordable and scalable support systems are needed as well as ongoing assessments and personalized support plans that focus on individual strengths and challenges in different contexts (college, work, community life) across the life span. This requires adaptive interventions and regular consultation with and between stakeholders. It also requires a rigorous approach to measuring outcomes that are not one-size-fits-all and do not expect everyone to reach, or have, the same goals. To meet these needs, the investigators leverage an already successful technology platform with two conversational-relational agents to be a digital companion and coach to autistic young adults (AYA, ages 18 to 35 years). The technology will be used to scale a strong theoretical and conceptual approach that has proven successful in meeting the individual needs and personalized outcomes of autistic students through a collaborative consultation model for promoting competency and success (COMPASS) combined with Goal Attainment Scaling (GAS). To deliver personalized coaching, empathy, and outcomes at scale, GAS/COMPASS was translated into software-driven evidence-based coaching protocols in collaboration with clinical, academic, and community partners. In this study, the digital coaching program and all research protocols are pilot tested in a 10-week experiential trial with AYA.

Recruiting
Has No Placebo

Indiana Institute on Disability and Community (+2 Sites)

Chantal Kerssens, PhD

Friendi.fi Corporation

Have you considered Abilify clinical trials?

We made a collection of clinical trials featuring Abilify, we think they might fit your search criteria.
Go to Trials